TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient, age \>19, scheduled for breast cancer surgery under general anesthesia~Exclusion Criteria:~* Patients who are not alert before procedure~* Day surgery~* BMI ≥35~* Hemodynamicaly unstable patients before procedure~* Patients with history of neromuscular disease or drug use affecting neuromuscular function.~* Patients with history of adverse reaction of allergic reaction to study drugs~* Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support~* Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h~* Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption~* Alcohol or drug dependence~* Organic brain disorder~* Patients with hypersensitive to beans or peanut~* Patients who refuse to participate

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remimazolam with flumazenil (Type: EXPERIMENTAL): Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.
- Propofol-based total intravenous anesthesia (Type: ACTIVE_COMPARATOR): Patients allocated to the propofol-based total intravenous anesthesia group receive propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years and older.~* Chronic myeloid leukemia (CML)~* Previous treatment with imatinib at a dose of \>600 mg/day AND the development of progressive disease while receiving imatinib at that dose, OR~* CML with resistance to imatinib at a dose less than or equal to 600 mg/day with genetic mutation in the BCR-ABL gene that is associated with a high level of resistance to imatinib, OR~* Intolerance to imatinib at any dose~* Adequate organ function~* Women who are able to bear children must have a negative serum or urine pregnancy test. Adequate methods of contraception must be used throughout the study to avoid pregnancy for the entire interval of at least 1 month before and 3 months after completion of the study medication.~Exclusion Criteria:~* Woman who are pregnant or breastfeeding~* Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above~* Previous diagnosis of accelerated phase or blast crisis CML.~* Participants who are eligible and willing to undergo transplantation during the screening period~* Uncontrolled or significant cardiovascular disease~* Use of imatinib within 7 days.~* Use of interferon or cytarabine within 14 days~* Use of a targeted small-molecule anticancer agent within 14 days~* Use of certain medication that carry a known side effect risk of Torsade de Pointes - Certain medications that irreversibly inhibit platelet function or anticoagulants~* Prior therapy with dasatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib, 70 mg twice daily (BID) (Type: EXPERIMENTAL): Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: APG101 in Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with a recurrence / progression of glioblastoma either not being eligible for tumour resection or having macroscopic residual tumour after resection of the recurrence~* Diagnosis of glioblastoma must be proven histologically and progress must be documented by MRI. MRI images must not be older than 2 weeks before first dosing/start of RT~* Not more than two prior therapy regimens including one or two resections, one or two chemotherapies of which one must have been TMZ-containing and one radiotherapy (RT) for the brain tumour~* Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at least 8 months since the end of preirradiation~* Candidate for reirradiation with recurrent tumour visible on MRI-T1 (Gd) and with the largest diameter measuring 1 cm to 4 cm~* Informed consent~* Age at least 18 years, smoking or non-smoking, of any ethnic origin~* Karnofsky performance index (KPI) ≥ 60%~* Neutrophile counts \> 1500/μl / Platelet counts \> 80.000/μl / Haemoglobin \> 10 g/dl / Serum creatinine \< 1.5-fold upper normal range / Bilirubin, AST or ALT \< 2,5-fold upper normal range unless attributed to anticonvulsants / Alkaline phosphatase \< 2,5-fold upper normal range~* Adequate contraception~* Stable or decreasing treatment with steroids within 5 days before treatment start~Exclusion Criteria:~* More than one RT of brain, prior first radiotherapy with more than 60 Gy~* Cumulative total dose on the optical chiasm \>54 Gy for 2 Gy/fraction, α/β=2~* Prior treatment with bevacizumab, iodine seeds and/or brachytherapy~* Unable to undergo MRI~* Past medical history of diseases with poor prognosis according to the judgement of the Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation~* HIV or hepatitis infection~* Pregnancy or breast feeding~* Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion~* Known active coronary artery disease, significant cardiac arrhythmias or severe congestive heart failure (NYHA class III - IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Re-Irradiation (Type: ACTIVE_COMPARATOR): 33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
- Re-Irradiation + APG101 (Type: EXPERIMENTAL): 66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Dose Effectiveness of Vitamin D Supplementation During Pregnancy- a Dose Comparison Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women aged 15 - 45 years~* Less than 16 weeks pregnant from Last menstrual period.~* Agree to take part in this study, will be enrolled.~Exclusion Criteria:~* Pregnant women with pre existing type 1 or type II diabetes,~* Pregnant women with pre existing hypertension~* Women with multiple fetuses, babies (twins, triplets)~* Women with fetal anomaly in scan~* Refuse to participate in the study

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Intervention Group (Type: ACTIVE_COMPARATOR): Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
- Arm 2 intervention group (Type: ACTIVE_COMPARATOR): Arm 2 is receiving vitamin D supplementation in 4000/IU per day
- Arm 3 control group (Type: ACTIVE_COMPARATOR): Arm 3 is receiving vitamin D supplementation in 400 IU/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing the informed consent~* Diagnosed with T1DM (Type 1 Diabetes Mellitus) (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) equal or above 1 year prior to the day of screening~* Using the same Medtronic pump (Minimed 530G (551/751), Paradigm Veo (554/754), Paradigm Revel (523/723), Paradigm (522/722)) for CSII in a basal-bolus regimen with a rapid acting insulin analogue for at least six months prior to screening and willing to stay on the same pump model throughout the trial (if the model is changed the change should not exceed 7 consecutive days.)~* HbA1c (glycosylated haemoglobin) 7.0-9.0% (53-75 mmol/mol) as assessed by central laboratory at screening~* Body mass index (BMI) below or equal to 35.0 kg/m\^2 at screening~* Ability and willingness to take at least 3 daily meal-time insulin bolus infusions every day throughout the trial~Exclusion Criteria:~* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening~* History of hospitalization for ketoacidosis below or equal to 180 days prior to the day of screening~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening~* Any condition which, in the opinion of the Investigator, might jeopardise a Subject's safety or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Faster-acting insulin aspart CSII (Type: EXPERIMENTAL): None
- NovoRapid® CSII (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 65 years or older generally in good health as determined by medical history, physical assessment and clinical judgment of the investigator.~Exclusion Criteria:~* Subjects who have received influenza vaccine within the past 6 month and who have received adjuvanted vaccine in the past two years.~* Subjects with hypersensitivity to vaccine components. Subjects who are on or were recently on immunosuppressive therapy.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: ACTIVE_COMPARATOR): None
- 5 (Type: ACTIVE_COMPARATOR): None
- 6 (Type: ACTIVE_COMPARATOR): None
- 7 (Type: ACTIVE_COMPARATOR): None
- 8 (Type: ACTIVE_COMPARATOR): None
- 9 (Type: ACTIVE_COMPARATOR): None
- 10 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pain Medicine for Wound Care Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults patients (≥ 21 years) have to have an open wound with duration of no more than 10 days that requires wound care~* be able to self-report their pain~* had a pain intensity score \> 3 during previous wound care procedure~* has intravenous access~Exclusion Criteria:~* Patients with an injury that impairs sensation in the wound area according to a medical diagnosis~* has an allergy to morphine or ketamine~* has not received morphine previously~* In addition, patients who are 65 years of age or older.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Morphine plus Ketamine, then Morphine plus Saline (placebo) (Type: ACTIVE_COMPARATOR): During the first wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK). Then, during the second wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS).
- Morphine plus Saline (placebo), then Morphine plus Ketamine (Type: PLACEBO_COMPARATOR): During the first wound care procedure, patients received morphine 0.1 mg/kg (a maximum dose of 8 mg) plus saline (MS). Then, during the second wound care procedure, patients received morphine 0.05 mg/kg (a maximum dose of 4mg) plus ketamine 0.25 mg/kg (MK)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole (NEXIUM) vs. Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects considered suitable for surgical treatment and long-term management of esomeprazole.~* History of chronic reflux esophagitis or symptomatic GERD~Exclusion Criteria:~* History of esophageal, gastric, or duodenal surgery predicted to influence negatively on subsequent treatment within the study.~* Contraindication to the study drug.~* Pregnancy, lactating or of child-bearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Surgery
- 2 (Type: EXPERIMENTAL): Esomeprazole (NEXIUM) therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pseudophakic or phakic and scheduled for a cataract operation~* Macular oedema due to DME~Exclusion Criteria:~* Previous Ozurdex® treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ozurdex® (dexamethasone intravitreal implant) (Type: None): Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~* Able to provide written informed consent~* Healthy male or female between 18 to 45 years of age, inclusive at the time of screening~* Additional inclusion criteria apply~Part B:~* 18 - 55 years old inclusive at Screening~* Active but clinically stable, plaque psoriasis~* Psoriasis involving ≥ 10% of the body surface area~* A minimum PASI score of ≥ 10 obtained during the screening period~* Additional inclusion criteria apply~Exclusion Criteria:~Part A:~* History or evidence of a clinically significant disorder (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric), condition or disease that, in the opinion of the Investigator and Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures or completion~* Underlying condition that predisposes the subject to infections (eg, uncontrolled diabetes - HbA1c \> 7%, history of splenectomy)~* Additional exclusion criteria apply~Part B:~* Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit~* Evidence of skin conditions other than psoriasis (eg, eczema) at the time of the screening visit or between the screening visit and study drug initiation that would interfere with evaluations of the effect of investigational product on psoriasis~* Any condition that, in the judgment of the investigator, might cause this study to be detrimental to the subject~* Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo treatment
- 140 mg SC (Type: EXPERIMENTAL): 140 mg SC PsO
- 350 mg SC (Type: ACTIVE_COMPARATOR): 350 mg SC PsO
- 700 mg IV (Type: EXPERIMENTAL): 700 mg IV PsO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients satisfying the following criteria will be considered the screening population and will be eligible for participation:~* Age \> 18 years male or female.~* Scheduled for any non-mechanical valve and/or CABG (structural heart) procedure where direct access to the LAA is expected.~* No documented preoperative AF.~* CHA2DS2-VASc score of =\> 2.~* HASBLED score of =\> 2.~* Acceptable surgical candidate, including use of general anesthesia.~* Willing and able to provide written informed consent.~Exclusion Criteria:~Patients satisfying the following criteria will not be eligible for participation:~* Redo cardiac surgery.~* Mechanical heart valve or other anticipated or current requirement for anticoagulation therapy during the post-operative (30 day) period.~* Hypercoagulability conditions that may confound the study.~* Ejection Fraction \< 30.~* Left Atrium \> 6 cm.~* Severe Diastolic Dysfunction.~* Requires anticoagulation therapy.~* Patient had a stroke/cerebrovascular accident (CVA) within previous 30 days prior to signing informed consent.~Intra-Operative Exclusion Criteria~* Presence of thrombus in the left atrium or LAA.~* LAA tissue is deemed friable or has significant adhesions (as evaluated by the surgeon) near or on the LAA making AtriClip placement overly risky.~* Left atrial appendage is outside the range of manufacturer's recommendations - width \< 29mm or \> 50mm.~* Direct visualization access is not available for AtriClip placement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAA Exclusion with AtriClip® (Type: OTHER): LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
- Medical Management (Type: ACTIVE_COMPARATOR): Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject must have surgically unresectable metastatic colorectal carcinoma.~* The subjects who have received and failed Ilinotecan, oxaliplatin and fluoropyrimidine-based chemotherapy~* ECOG PS 0-2~Exclusion Criteria:~* Subjects with symptomatic cerebral metastasis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete